CURRICULUM VITAE

Name: Tae-You Kim, M.D., Ph.D.
Current Position:
Professor
Department of Internal Medicine
Seoul National University Hospital
Country: KOREA

Educational Background:
1980.3-1982.2: Premedical Course, Seoul National University College of Natural Science, Seoul, Korea
1982.3-1986.2: M.D. Seoul National University College of Medicine, Seoul, Korea
1992.3-1994.2: M.S. Graduate school, Seoul National University College of Medicine, Seoul, Korea
1994.3-1996.8: Ph.D. Graduate school, Seoul National University College of Medicine, Seoul, Korea

Professional Experiences:
1990.5 - 1994.2: Resident in Internal Medicine, Seoul National University Hospital, Seoul, Korea
1994.3-1995.3: Clinical Fellow in Hematology/Oncology, Seoul National University Hospital, Seoul, Korea
1995.4 - 1998.5: Chief in Section of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea
1998.6 - 2000.1: Research Fellow, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
2000.9 – 2004. 8: Assistant Professor, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
2004.12-2005.12: Adjunct Assistant Professor, Department of Biochemistry & Molecular Biology, University of Florida, Gainesville, USA
2004.9 – 2009.8: Associate Professor, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
2009.9 – present: Professor, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Professional Organizations:
2011.3-2015.1: Director of Clinical Services, Seoul National University Cancer Hospital
2015.2-2017.1: Director, Seoul National University Cancer Hospital
2016.1 –present: Member, National Academy of Medicine of Korea
2016.6-2018.6: Chief of Academic Committee, Korea Cancer Association
2017.1-2017.12: President, Korea Genome Organization
2017.11-present: Director, Center for Precision Medicine, Seoul National University

KSMO 2019 Secretariat [P&M]: 3F, MS B/D, 12, Eonju-ro 79 gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX +82-2-557-8428 E-mail: info@ksmo2019.org

2018.6-present: Chairman, Board of Directors, Korean Society of Medical Oncology

Main Scientific Publications:

Han SW, **Kim TY**, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. "Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib" *J Clin Oncol*. 2005 Apr 10;23(11):2493-501

Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ, **Kim TY**. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. *J Mol Med*. 2007 Oct;85(10):1137-48

Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH, Kim DK, Bang YJ, **Kim TY**. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. *J Mol Med*. 2008 Jan;86(1):117-28

Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, **Kim TY**. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. *Mol Cancer Ther*. 2009 Sep;8(9):2526

Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Kim KY, Park SY,Lee DW, Won JK, Jeong SY, Park KJ, Park JG, Kang KH, Seo JS, Kim JI, **Kim TY**. RNA editing in *RHOQ* promotes invasion potential in colorectal cancer. *J Exp Med* . 2014 Apr 7;211(4):613-21.

Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, **Kim TY**. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. *Oncogene.* 2014 Jun 19;33(25):3334-41.

Kang JY, Song SH, Yun J, Jeon MS, Kim HP, Han SW, **Kim TY**. Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression. *Oncogene*. 2015 Nov 5;34(45):5677-84.

Yun J, Song SH, Kang JY, Park J, Kim HP, Han SW, **Kim TY**. Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability. *Nucleic Acids Res*. 2016 Jan 29;44(2):558-72.

Yun J, Song SH, Kim HP, Han SW, Yi EC, **Kim TY**. Dynamic cohesin-mediated chromatin architecture controls epithelial-mesenchymal plasticity in cancer. *EMBO reports*. 2016 Sep;17(9):1343-59.

Ahn J, Hwang B, Young Kim H, Jang H, Kim HP, Han SW, **Kim TY**, Hyun Lee J, Bang D. Asymmetrical barcode adapter-assisted recovery of duplicate reads and error correction strategy to detect rare mutations in circulating tumor DNA. *Sci Rep*. 2017 May 2;7:46678.

Song SH, Jeon MS, Nam JW, Kang JK, Lee YJ, Kang JY, Kim HP, Han SW, Kang GH, **Kim TY**. Aberrant GATA2 epigenetic dysregulation induces a GATA2/GATA6 switch in human

KSMO 2019 Secretariat [P&M]: 3F, MS B/D, 12, Eonju-ro 79 gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX +82-2-557-8428 E-mail: info@ksmo2019.org

gastric cancer. *Oncogene* (2018 Feb 22;37(8):993-1004)

KSMO 2019 Secretariat [P&M]: 3F, MS B/D, 12, Eonju-ro 79 gil, Gangnam-gu, Seoul, Korea Tel: +82-2-557-8422, 8423 FAX +82-2-557-8428 E-mail: info@ksmo2019.org